Dubai: Imagine standing in a room and watching a woolly mammoth move, hearing the rustle of its shaggy coat and feeling, for just a moment, as though a creature that vanished thousands of years ago ...
AZoLifeSciences on MSN
Human neurons reveal why some cells resist tau protein buildup
New research by UCLA Health and UC San Francisco has uncovered why certain brain cells are more resilient than others to the buildup of a toxic protein that is a hallmark of Alzheimer's disease and ...
Scientists have achieved a genetic feat once thought impossible: removing an entire extra human chromosome using gene-editing ...
New research by UCLA Health and UC San Francisco has uncovered why certain brain cells are more resilient than others to the buildup of a toxic protein that is a hallmark of Alzheimer's disease and ...
However, there are certain things AI can't do -- and may never be able to do. One of them is to cure diseases. Biotech companies that develop and market breakthrough therapies for, thus far, ...
The approach uses an iteration of the SHERLOCK technology exclusively licensed to OraSure Technologies' subsidiary, Sherlock Biosciences.
DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial.
When Feng Zhang was in his early 30s, he used a set of genes found in bacteria called CRISPR to pioneer a new kind of gene ...
A San Diego research team has snagged a $7.4 million state award to push a gene-edited stem cell therapy for Friedreich’s ataxia toward human testing. The funding will cover final safety studies, ...
Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...
29d
Cathie Wood's moves entering 2026: bets on gene-editing and genomics names, adds BEAM, TWST, NTLA
Cathie Wood’s latest moves entering 2026 focused on early-stage biotechnology firms while cutting exposure to consumer technology, diagnostics and space tech companies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results